MAPT and Alzheimer disease: The biomarkers of AD include Magnetic Resonance Imaging, functional Magnetic Resonance Imaging (fMRI), Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET), Amyloid-Positron Emission Tomography (Amyloid-PET), Tau-Positron Emission Tomography (Tau-PET), electroencephalography (EEG), magnetoencephalography (MEG), speech transcripts, genetic measures and cerebrospinal fluid (CSF) measures.